PICT-1
Oncology (e.g., HR+ Breast Cancer)
Key Facts
About PIC Therapeutics
PIC Therapeutics is pioneering a novel approach in oncology and metabolic disease by targeting the eIF4A RNA helicase, a core component of the eIF4F translation initiation complex. The company's lead program, PICT-1, is a first-in-class, orally available small molecule designed to disrupt the translation of specific oncogenic mRNAs, offering a potential new treatment paradigm for cancers driven by dysregulated protein synthesis. Backed by venture capital investors and led by a team with deep experience in drug discovery and translation biology, PIC Therapeutics is advancing its platform from preclinical proof-of-concept towards clinical development. Its strategy focuses on addressing high-unmet-need cancers with known dependencies on eIF4F, such as certain breast cancers.
View full company profile